The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Efficacy and safety of acalabrutinib treatment in very old (≥80y) and/or frail patients with CLL
Florian Simon, MD, University Hospital Cologne, Cologne, Germany, comments on the efficacy and safety of acalabrutinib treatment in very old (≥80y) and/or frail patients with chronic lymphocytic leukemia (CLL). Dr Simon highlights that the CLL-Frail trial (NCT04883749) found that 93% of patients responded to treatment, not only tolerating treatment but also experiencing an improvement in their perceived frailty. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
